COMMUNIQUÉS West-GlobeNewswire

BioCardia to Host Q1 2026 Financial Results and Corporate Update Conference Call on May 15, 2026
11/05/2026
SUNNYVALE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it [...]
Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results
11/05/2026
Delivered Q1 2026 Total Revenues of $149.4 Million Results include 28% YoY Increase in Net Product Revenues from FIRDAPSE® & AGAMREE® Reported Cash and Cash Equivalents of $755.9 Million and No Funded Debt as of [...]
Sotera Health Announces Secondary Offering of Common Stock
11/05/2026
CLEVELAND, May 11, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 31,838,253 shares of its common stock, par value $0. [...]
CORRECTION – Human Appeal Launches Hajj Step Challenge, Turning Steps into a Lifeline
11/05/2026
Participants challenged to walk 10,000 steps a day during the 10 most sacred days of the Islamic Calendar, raising funds to deliver vital meals to those in need In a release issued earlier on Monday, May 11, under the [...]
Solana Company to Release First Quarter 2026 Operating Results on May 15, 2026
11/05/2026
NEWTOWN, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed company, today announced that the Company will release its first quarter operating results on [...]
Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026
11/05/2026
DURHAM, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT ) today announced that it will report its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provide a business [...]
Sanara MedTech Inc. Reports First Quarter 2026 Financial Results (Unaudited)
11/05/2026
Net Revenue Growth of 19% and Net Profitability from Continuing Operations of $0.04 Per Fully Diluted Share for the Quarter FORT WORTH, TX, May 11, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” “Sanara MedTech [...]
Ceribell Reports First Quarter 2026 Financial Results
11/05/2026
SUNNYVALE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological [...]
FDA Advances Drug Repurposing to Address Unmet Medical Needs
11/05/2026
Agency is particularly focused on new uses to treat chronic or rare diseases White Oak, Md., May 11, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration today announced it is soliciting input on efforts with [...]
Cellectis publie ses résultats financiers du premier trimestre 2026
11/05/2026
Phase 2 pivot évaluant lasmé-cel dans la LAL-B en rechute ou réfractaire (étude BALLI-01) Analyse intermédiaire de phase 2 pivot attendue en Q4 2026 Dépôt de demande d'autorisation de mise sur le marché (BLA) prévu en [...]
Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update
11/05/2026
Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is progressing well with the interim analysis [...]
Cellectis Reports Financial Results for the First Quarter 2026
11/05/2026
Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) Pivotal Phase 2 first interim analysis expected in Q4 2026 BLA submission anticipated in 2028 Phase 1 with eti-cel in r/r NHL (NATHALI-01 trial) Full Phase 1 [...]
SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update
11/05/2026
Completed transformative acquisition of PXL-770, (now SCY-770), an innovative, highly selective, direct AMPK activator for the treatment of autosomal dominant polycystic kidney disease (ADPKD) A Phase 2 proof-of-concept [...]
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights
11/05/2026
Successfully completed chronic toxicology studies for icovamenib, providing the nonclinical support for advancing to chronic clinical dosing, beyond the 12-week clinical dosing that has been used to date Topline data [...]
CG Oncology’s Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC
11/05/2026
- First results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in High-Risk BCG-Exposed and BCG-Unresponsive patients to be presented - - Visit CG Oncology at booth #3051 - DALLAS, May [...]
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
11/05/2026
First participant dosed in FORTIFY, a Phase 1b indication expansion trial of PLN-101095 Oral presentation at AACR 2026 featured updated data from Phase 1 trial of PLN-101095 showing deepening of confirmed responses in [...]
Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates
11/05/2026
Maintained strong financial position with $596 million in cash, cash equivalents and marketable securities as of March 31, 2026 Continued execution across the oncology pipeline, with a strategic focus on three priority [...]
SI-BONE, Inc. Reports Financial Results for the First Quarter 2026 and Raises 2026 Guidance
11/05/2026
Delivered ~11% worldwide revenue growth, record physician engagement and ~440% improvement in adjusted EBITDA First Quarter 2026 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $ [...]
Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update
11/05/2026
– LOQTORZI ® net revenue of $11.8 million in Q1 2026 – – Patient accrual complete for 1L HCC Phase 2 randomized clinical trial for anti-IL27 casdozokitug, timing for data readouts tracking to projections – – Tagmokitug [...]

Pages